<DOC>
	<DOCNO>NCT00620438</DOCNO>
	<brief_summary>There increase number HIV-infected patient sub-Saharan Africa receive antiretroviral drug and/or rifampicin base antituberculous therapy . HIV infected patient increase risk contracting malaria . Increasing resistance anti-malarials chloroquine , amodiaquine , fansidar , sulphadoxine-pyrimethamine East West Africa lead WHO recommend artemether-lumefantrine ( Coartem®- Novartis ) first line therapy malaria adult child . As early 2004 , fourteen country sub-Saharan Africa adopt guideline national policy . There data interaction Coartem® antiretroviral agent . Both component Coartem® substrates 3A4 isoform cytochrome P450 . Despite lack data , antiretroviral drug and/or antituberculous drug addition Coartem® necessity co-prescribed daily African setting . Nevirapine , efavirenz rifampicin know inducer cytochrome P450 3A4 . A technical consultation convene WHO June , 2004 conclude additional research interaction antiretroviral antimalarial drug urgently need . We propose perform suite pharmacokinetic study evaluate interaction HIV infect Ugandan patient . The aim study evaluate pharmacokinetic interaction Coartem® commonly co-prescribed inducer 3A4 i.e . nevirapine , efavirenz rifampicin . 1 . Comparison steady state pharmacokinetics Coartem® HIV-infected patient prior commencement nevirapine nevirapine steady state 2 . Comparison steady state pharmacokinetics Coartem® HIV-infected patient prior commencement efavirenz efavirenz steady state 3 . Comparison steady state pharmacokinetics Coartem® Ugandan patient rifampicin steady state without rifampicin</brief_summary>
	<brief_title>Drug Interaction Between Coartem® Nevirapine , Efavirenz Rifampicin HIV Positive Ugandan Patients</brief_title>
	<detailed_description>Coartem® combination artemether lumefantrine use treatment uncomplicated falciparum malaria 1 . This oral combination seem well-tolerated useful treatment multi-drug resistant Plasmodium falciparum . This unique anti-malarial agent combine fast , short-acting artemether less potent , longer-acting lumefantrine . Original study combination demonstrate safety efficacy adult child uncomplicated falciparum malaria . 2,3 Additional study show superiority respect parasite clearance time versus halofantrine,4 chloroquine5 , mefloquine6 . Coartem® also demonstrate fast reduction parasite burden 24-hours versus halofantrine4 , chloroquine5 ( adult ) , chloroquine ( child ) 7 , mefloquine6 . Various study show artemether-lumefantrine superior 28-day cure rate , well time fever resolution compare antimalarial agents.1 Both component Coartem® discover China . Artemether isolate sweet wormwood , Atemisia annua , use traditional Chinese medicine 2000 year 1 . Lumefantrine synthetic compound , structural physiochemical characteristic ; mode action similar antimalarial , include quinine , mefloquine , halofantrine 8 . In vitro , two antimalarial agent show synergistic activity P.falciparum . Based vitro vivo study , 1:6 ratio artemether lumefantrine describe optimal . Thus , tablet manufacture 20mg artemether 120mg lumefantrine . 8 Currently two recommend dose regimen adult child 35 kg ; 12 year age old . In partially immune patient , 4-dose regimen recommend . Four tablet single dose take time diagnosis 8 , 24 , 48 hour post-initial dose . A different regimen recommend either non-immune patient patient area multi-drug resistance falciparum malaria problem . This 3-day regimen consist 4 tablet single dose give time diagnosis , 8 hour later twice daily follow two day . 1 Antimalarial Activity Mechanism Action : 1 , 8 The antimalarial activity artemether active metabolite , dihydroartemisinin ( DHA ) extensively study vitro . These potent antimalarial compound . The IC50 artemether range 0.1 20 nmol/L IC50 DHA range 0.1 15 nmol/L . In vitro study show artemether 2 3 time less active metabolite , DHA . The exact mechanisms action artemether lumefantrine unknown , agent appear act parasite 's organelle . Artemether 's action depend endoperoxide bridge , interact heme iron cause free radical damage malaria parasite . Lumefantrine likely interferes heme polymerization , critical detoxify pathway malaria parasite . Both agent may secondary action include inhibition parasite nucleic acid protein synthesis ; however , action well-described . The varied pharmacokinetic profile two antimalarial agent appear create synergistic effect . Artemether work rapidly decrease parasite load improve patient ' clinical symptom . Lumefantrine long-acting appear prevent recrudescence ( reappearance disease inadequate fail drug therapy ) . The different action two agent may also reduce emergence resistance . Artemether DHA show decrease parasite burden 104 per asexual life cycle 2 day . Thus , 3-day course combination therapy potentially decrease parasite burden 108 . Drug Interactions Pharmacokinetic electrocardiographic interaction artemether-lumefantrine mefloquine study 42 healthy volunteer . Like artemether-lumefantrine , mefloquine substrate CYP 3A4 ; however , also potential CYP 3A4 inhibitor . Pharmacokinetic parameter artemether , DHA , mefloquine unchanged ; however , lumefantrine concentration decrease 30-40 % give mefloquine . The clinical significance interaction know . Co-administration antimalarial agent result increased adverse effect . 13 An additional study evaluate effect concomitant administration ketoconazole , potent CYP 3A4 inhibitor , artemether-lumefantrine . The study carry 16 healthy volunteer receive single dos artemether-lumefantrine either alone combination multiple dose ketoconazole . Artemether , DHA , lumefantrine pharmacokinetics alter ketoconazole . AUC Cmax increase three compound terminal half-life increase artemether DHA . None change PK parameter great change observe healthy volunteer take artemether-lumefantrine high fat meal ( i.e . 16-fold increase AUC ) . There increase observe side effect electrocardiographic change . Dosage adjustment appear necessary concomitant ketoconazole administration.14 A study 42 healthy Caucasian volunteer conduct investigate pharmacokinetic electrocardiographic effect concomitant administration IV quinine artemether-lumefantrine . QTc prolongation associate artemether-lumefantrine administration alone ; however transient increase QTc interval note combination group . PK variables lumefantrine quinine unchanged , artemether DHA plasma concentration decrease concomitant quinine administration . The exact mechanism decrease could explain result study.15 Artemether metabolized via CYP 3A4 dihydroartemisinin ( although compound antimalarial activity , dihydroartemisinin great potency ) . Induction CYP 3A4 would increase dihydroartemisinin decrease artemether . Study objectives General objective To evaluate pharmacokinetic interaction Coartem® commonly co-prescribed inducer 3A4 i.e . nevirapine , efavirenz rifampicin HIV positive patient . Specific objectives 1 . To compare steady state pharmacokinetics Coartem® HIV-infected patient prior commencement nevirapine nevirapine steady state 2 . To compare steady state pharmacokinetics Coartem® HIV-infected patient prior commencement efavirenz efavirenz steady state 3 . To compare steady state pharmacokinetics Coartem® Ugandan patient rifampicin steady state without rifampicin therapy</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Age eighteen year Ability provide full write informed consent Confirmed diagnosis HIV infection Haemoglobin &lt; 8g/dl Liver renal function test &gt; 3 time upper limit normal Pregnancy Use know inhibitor inducer cytochrome P450 Pglycoprotein . Use herbal medication ( information obtain patient ' medication history interview patient ) Abnormal EKG ie QTc ( Rate adjust QT interval ) &gt; 450ms ( men ) &gt; 470ms ( woman ) Intercurrent Illness include malaria Known hypersensitivity artemisininderivatives , halofantrine lumefantrine History cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Lumefantrine</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Rifampicin</keyword>
	<keyword>HIV</keyword>
</DOC>